Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$716.00M+561.47%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- August James Troendle
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 6,600
- Beta
- 1.12
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 8.08
Financials
Revenue
$716.00M+561.5%Net Income
$137.46MEBITDA
$177.49M+903.4%Free Cash Flow
$196.44M+740.5%EPS (diluted)
$4.84Shares Outstanding (diluted)
28.37M-30.2%Operating Expenses
$51.77MCash & Debt
$705.32MReturn of Capital
$0.00Revenue by Segment (annual)
$2.53BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.53B | $451.12M | $15.64 |
| 2024 | $2.11B | $404.39M | $13.06 |
| 2023 | $1.89B | $282.81M | $9.20 |
| 2022 | $1.46B | $245.37M | $7.57 |
| 2021 | $1.14B | $181.85M | $5.06 |
| 2020 | $925.92M | $145.38M | $4.07 |
| 2019 | $860.97M | $100.44M | $2.79 |
| 2018 | $704.59M | $73.19M | $2.05 |
| 2017 | $436.15M | $39.12M | $1.00 |
| 2016 | $421.58M | $13.43M | $0.38 |
| 2015 | $359.06M | $-8.67M | $-0.28 |
| 2014 | $290.04M | $-15.57M | $-0.53 |
| 2013 | $272.89M | $24.84M | $1.33 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MEDP's reported EPS growth of 22.8% a year over 12 years.
- EPS in 5 years
- $43.67
- Implied price
- $1,572
- Return from $633.98
- 19.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $781.65 — today's price is already 18.9% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 26 | 31 | 36 | 41 | 46 |
|---|---|---|---|---|---|
| 12.8% | 3.2% | 6.9% | 10.2% | 13.1% | 15.7% |
| 17.8% | 7.8% | 11.6% | 15.0% | 18.1% | 20.8% |
| 22.8% | 12.4% | 16.4% | 19.9% | 23.1% | 25.9% |
| 27.8% | 16.9% | 21.1% | 24.8% | 28.1% | 31.1% |
| 32.8% | 21.5% | 25.9% | 29.7% | 33.1% | 36.2% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (26)
- Newszacks.com·23d ago·Positive
Medpace (MEDP) is a Great Momentum Stock: Should You Buy? Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·24d ago·Positive
Medpace Holdings, Inc. (MEDP) Hits Fresh High: Is There Still Room to Run? Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗ - Newszacks.com·27d ago·Positive
Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes" Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
View source ↗ - Newszacks.com·27d ago·Positive
All You Need to Know About Medpace (MEDP) Rating Upgrade to Buy Medpace (MEDP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newszacks.com·27d ago·Positive
Here's Why Medpace (MEDP) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - News (RSS)seekingalpha·28d ago·Negative
Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate
View source ↗ - Newsseekingalpha.com·28d ago·Negative
Medpace: Downgrade 'Hold' Revenue Growth Guidance Change And Slightly Lower Backlog Conversion Rate Medpace Holdings is downgraded from "Buy" to "Hold" due to decelerating growth metrics and underwhelming forward guidance. Q3 2026 Net New Business Awards rose just 10.6%, a sharp slowdown from Q2's 28.2% growth, signaling weaker contract momentum. Revenue growth in Q3 2026 was 8.5% to $716M, below the prior quarter's 17.2% pace and only modestly above consensus.
View source ↗ - Newsfool.com·30d ago·Positive
Medpace: 3 Key Takeaways for Long-Term Investors Net new business awards reached $873 million in the third quarter. Ending backlog reached $3.2 billion, up 5.6% year over year.
View source ↗ - Newsmarketbeat.com·31d ago·Positive
Medpace Q3 Earnings Call Highlights Medpace NASDAQ: MEDP reported third-quarter 2026 revenue growth of 8.5% and record net new business awards, while management said the clinical research organization continues to see a strong operating environment marked by healthy request-for-proposal activity, initial award notifications and win rates.
View source ↗ - News (RSS)seekingalpha·32d ago·Neutral
Medpace raises 2026 EPS guidance range
View source ↗ - Newszacks.com·32d ago·Positive
Medpace (MEDP) Q3 Earnings and Revenues Beat Estimates Medpace (MEDP) came out with quarterly earnings of $4.84 per share, beating the Zacks Consensus Estimate of $4.45 per share. This compares to earnings of $3.86 per share a year ago.
View source ↗ - Newsgurufocus.com·32d ago·Positive
A Look at Medpace Holdings Inc (MEDP) After 6.4% Gain -- GF Value $539.19 vs Price $662.48 On October 21, 2026, Medpace Holdings Inc (MEDP) shares rose 6.4% to $662.48, continuing a strong upward trend that has seen the stock increase 21.4% over the p
View source ↗ - News (RSS)seekingalpha·40d ago·Positive
Medpace: Strong Execution Faces A High-Growth Bar
View source ↗ - Newszacks.com·40d ago·Neutral
Medpace (MEDP) Dips More Than Broader Market: What You Should Know In the latest trading session, Medpace (MEDP) closed at $609.89, marking a -1.64% move from the previous day.
View source ↗ - News (RSS)seekingalpha·40d ago·Negative
Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One
View source ↗ - Newsseekingalpha.com·40d ago·Positive
Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One Medpace Holdings is misunderstood due to its faster, cleaner backlog burn, which the market misinterprets as a growth ceiling rather than a quality upgrade. Q2 revenues rose 17.2% to $707.3M, with EBITDA margin improving beneath headline pass-through cost effects; guidance for FY26 was raised across revenue, EBITDA, and EPS. Customer prepayments fund operations and share buybacks, supporting EPS growth and providing a buffer…
View source ↗ - Newszacks.com·47d ago·Neutral
Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors Medpace (MEDP) concluded the recent trading session at $602.9, signifying a -2.84% move from its prior day's close.
View source ↗ - News (Marketaux)gurufocus.com·53d ago·Positive
UBS Initiates Coverage of Medpace (MEDP) with Neutral Rating and $673 Price Target On September 30, 2026, UBS began coverag[+330 characters]
View source ↗ - Newszacks.com·54d ago·Negative
Medpace (MEDP) Rises As Market Takes a Dip: Key Facts In the closing of the recent trading day, Medpace (MEDP) stood at $622.11, denoting a +1% move from the preceding trading day.
View source ↗ - Newsbusinesswire.com·61d ago·Positive
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026 CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its third quarter 2026 financial results after the market close on Wednesday, October 21, 2026. The Company will host a conference call the following morning, Thursday, October 22, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must reg…
View source ↗ - Newszacks.com·62d ago·Positive
Medpace (MEDP) Outperforms Broader Market: What You Need to Know Medpace (MEDP) concluded the recent trading session at $624.2, signifying a +1.94% move from its prior day's close.
View source ↗ - 4chan /biz/biz·68d ago·Neutral
>>62692571 I saw that it was pretty funny maybe he can change even if he tries, even if he wants to >HLMN >MEDP
View source ↗ - Newszacks.com·69d ago·Neutral
Medpace (MEDP) Ascends While Market Falls: Some Facts to Note In the latest trading session, Medpace (MEDP) closed at $595.41, marking a +1.34% move from the previous day.
View source ↗ - Newszacks.com·93d ago·Neutral
Why Is Medpace (MEDP) Up 1.1% Since Last Earnings Report? Medpace (MEDP) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·96d ago·Neutral
Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
View source ↗ - Newszacks.com·104d ago·Positive
Here's Why Medpace (MEDP) is a Strong Growth Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗
Earnings
Mon, Feb 8(in 3 months)
Consensus estimate $4.82 per share
Typical surprise +9.2% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Oct 21$4.84 vs $4.44beat
- Wed, Jul 22$4.25 vs $3.98beat
- Wed, Apr 22$4.28 vs $3.92beat
- Mon, Feb 9$4.67 vs $4.19beat
- Wed, Oct 22$3.86 vs $3.53beat
- Mon, Jul 21$3.10 vs $2.98beat
Estimates and results for MEDP via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MEDP officers and directors.
- Bought
- —
- Sold
- $230.2m
0 trades
35 trades
- Ewald Stephen Psold
- Burwig Susan Esold
- Burwig Susan Esold
- Troendle August J.sold
- Troendle August J.sold
- Troendle August J.sold
- Troendle August J.sold
- Troendle August J.sold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- David Taylorhouse · OH02 · disclosed May 29, 2026 (14d later)Buy$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Mar 9, 2026 (11d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Feb 13, 2026 (29d later)Sell$15,001 - $50,000
- David Taylorhouse · OH02 · disclosed Feb 3, 2026 (5d later)Buy$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Feb 3, 2026 (18d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 18, 2025 (40d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (42d later)Sell$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Sep 3, 2025 (42d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Aug 15, 2025 (22d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (22d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Feb 14, 2025 (32d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Aug 15, 2024 (20d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (18d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Feb 15, 2024 (22d later)Sell$1,001 - $15,000
- Michael Guesthouse · MS03 · disclosed Dec 11, 2023 (28d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Aug 29, 2022 (38d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 15, 2021 (20d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jan 11, 2021 (32d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jan 7, 2021 (30d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 5, 2020 (2d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
